{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:59:14Z","timestamp":1786978754642,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":94,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030550349","type":"print"},{"value":"9783030550356","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-55035-6_17","type":"book-chapter","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T12:07:20Z","timestamp":1615896440000},"page":"251-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders"],"prefix":"10.1007","author":[{"given":"Andr\u00e9 S. L. M.","family":"Antunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ria","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Crunfli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor C.","family":"Carregari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Martins-de-Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"17_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1089\/omi.2016.0106","volume":"20","author":"M Kori","year":"2016","unstructured":"Kori M, Ayd\u0131n B, Unal S, Arga KY, Kazan D (2016) Metabolic biomarkers and neurodegeneration: a pathway enrichment analysis of Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis. OMICS 20:645\u2013661","journal-title":"OMICS"},{"key":"17_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J van Os","year":"2009","unstructured":"van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635\u2013645","journal-title":"Lancet"},{"key":"17_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3389\/fnins.2017.00493","volume":"11","author":"GS Zuccoli","year":"2017","unstructured":"Zuccoli GS, Saia-Cereda VM, Nascimento JM, Martins-de-Souza D (2017) The energy metabolism dysfunction in psychiatric disorders postmortem brains: focus on proteomic evidence. Front Neurosci 11:493. https:\/\/doi.org\/10.3389\/fnins.2017.00493","journal-title":"Front Neurosci"},{"key":"17_CR4","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.metabol.2016.05.018","volume":"65","author":"C Procaccini","year":"2016","unstructured":"Procaccini C, Santopaolo M, Faicchia D, Colamatteo A, Formisano L, de Candia P et al (2016) Role of metabolism in neurodegenerative disorders. Metabolism 65:1376\u20131390","journal-title":"Metabolism"},{"key":"17_CR5","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.2174\/0929867324666170705120038","volume":"26","author":"B Szatmari","year":"2019","unstructured":"Szatmari B, Balicza P, Nemeth G, Molnar MJ (2019) The Panomics approach in neurodegenerative disorders. Curr Med Chem 26:1712\u20131720","journal-title":"Curr Med Chem"},{"key":"17_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1196\/annals.1418.024","volume":"1144","author":"JE Krause","year":"2008","unstructured":"Krause JE, Chenard BL (2008) Opportunities and challenges in the discovery of new central nervous system drugs. Ann N Y Acad Sci 1144:243\u2013250","journal-title":"Ann N Y Acad Sci"},{"key":"17_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ddr.21368","volume":"77","author":"CJ Van der Schyf","year":"2016","unstructured":"Van der Schyf CJ (2016) Psychotropic drug development strategies that target neuropsychiatric etiologies in Alzheimer\u2019s and Parkinson\u2019s diseases. Drug Dev Res 77:458\u2013468","journal-title":"Drug Dev Res"},{"key":"17_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-pharmtox-010716-104624","volume":"57","author":"PH Hutson","year":"2017","unstructured":"Hutson PH, Clark JA, Cross AJ (2017) CNS target identification and validation: avoiding the valley of death or naive optimism? Annu Rev Pharmacol Toxicol 57:171\u2013187","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"17_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/17460441.2017.1380623","volume":"12","author":"ECM de Lange","year":"2017","unstructured":"de Lange ECM, van den Brink W, Yamamoto Y, de Witte WEA, Wong YC (2017) Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics. Expert Opin Drug Discov 12:1207\u20131218","journal-title":"Expert Opin Drug Discov"},{"key":"17_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11481-014-9578-5","volume":"10","author":"M-E Dumas","year":"2015","unstructured":"Dumas M-E, Davidovic L (2015) Metabolic profiling and phenotyping of central nervous system diseases: metabolites bring insights into brain dysfunctions. J Neuroimmune Pharmacol 10:402\u2013424","journal-title":"J Neuroimmune Pharmacol"},{"key":"17_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1083\/jcb.201004052","volume":"190","author":"TC Walther","year":"2010","unstructured":"Walther TC, Mann M (2010) Mass spectrometry-based proteomics in cell biology. J Cell Biol 190:491\u2013500","journal-title":"J Cell Biol"},{"key":"17_CR12","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/bmc.3157","volume":"28","author":"K Wang","year":"2014","unstructured":"Wang K, Huang C, Nice E (2014) Recent advances in proteomics: towards the human proteome. Biomed Chromatogr 28:848\u2013857","journal-title":"Biomed Chromatogr"},{"key":"17_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nature01511","volume":"422","author":"R Aebersold","year":"2003","unstructured":"Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198\u2013207","journal-title":"Nature"},{"key":"17_CR14","doi-asserted-by":"publisher","first-page":"197A","DOI":"10.1021\/ac0415657","volume":"76","author":"NL Kelleher","year":"2004","unstructured":"Kelleher NL (2004) Top-down proteomics. Anal Chem 76:197A\u2013203A","journal-title":"Anal Chem"},{"key":"17_CR15","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1007\/s13361-019-02315-2","volume":"30","author":"D Yu","year":"2019","unstructured":"Yu D, Wang Z, Cupp-Sutton KA, Liu X, Wu S (2019) Deep intact proteoform characterization in human cell lysate using high-pH and low-pH reversed-phase liquid chromatography. J Am Soc Mass Spectrom 30:2502\u20132513","journal-title":"J Am Soc Mass Spectrom"},{"key":"17_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1039\/C9MO00154A","volume":"16","author":"KA Cupp-Sutton","year":"2020","unstructured":"Cupp-Sutton KA, Wu S (2020) High-throughput quantitative top-down proteomics. Mol Omics 16:91\u201399","journal-title":"Mol Omics"},{"key":"17_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s11427-017-9175-2","volume":"60","author":"X Li","year":"2017","unstructured":"Li X, Wang W, Chen J (2017) Recent progress in mass spectrometry proteomics for biomedical research. Sci China Life Sci 60:1093\u20131113","journal-title":"Sci China Life Sci"},{"key":"17_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cbpa.2008.07.024","volume":"12","author":"X Han","year":"2008","unstructured":"Han X, Aslanian A, Yates JR 3rd (2008) Mass spectrometry for proteomics. Curr Opin Chem Biol 12:483\u2013490","journal-title":"Curr Opin Chem Biol"},{"key":"17_CR19","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nbt1004-1215","volume":"22","author":"L Hood","year":"2004","unstructured":"Hood L, Perlmutter RM (2004) The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 22:1215\u20131217","journal-title":"Nat Biotechnol"},{"key":"17_CR20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nmeth1093","volume":"4","author":"T K\u00f6cher","year":"2007","unstructured":"K\u00f6cher T, Superti-Furga G (2007) Mass spectrometry-based functional proteomics: from molecular machines to protein networks. Nat Methods 4:807\u2013815","journal-title":"Nat Methods"},{"key":"17_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/database\/bay083","volume":"2018","author":"Z Tanoli","year":"2018","unstructured":"Tanoli Z, Alam Z, V\u00e4h\u00e4-Koskela M, Ravikumar B, Malyutina A, Jaiswal A et al (2018) Drug target commons 2.0: a community platform for systematic analysis of drug-target interaction profiles. Database 2018:1\u201313. https:\/\/doi.org\/10.1093\/database\/bay083","journal-title":"Database"},{"issue":"3","key":"17_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/proteomes4030028","volume":"4","author":"H Matthews","year":"2016","unstructured":"Matthews H, Hanison J, Nirmalan N (2016) \u201cOmics\u201d-Informed drug and biomarker discovery: opportunities, challenges and future perspectives. Proteomes 4(3):28. https:\/\/doi.org\/10.3390\/proteomes4030028","journal-title":"Proteomes"},{"key":"17_CR23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/nrd1202","volume":"2","author":"MA Lindsay","year":"2003","unstructured":"Lindsay MA (2003) Target discovery. Nat Rev Drug Discov 2:831\u2013838","journal-title":"Nat Rev Drug Discov"},{"key":"17_CR24","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1093\/ndt\/gfv364","volume":"31","author":"K Cisek","year":"2016","unstructured":"Cisek K, Krochmal M, Klein J, Mischak H (2016) The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease. Nephrol Dial Transplant 31:2003\u20132011","journal-title":"Nephrol Dial Transplant"},{"key":"17_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.gpb.2014.10.002","volume":"12","author":"L Jin","year":"2014","unstructured":"Jin L, Zuo XY, Su WY, Zhao XL, Yuan MQ, Han LZ et al (2014) Pathway-based analysis tools for complex diseases: a review. Genomics Proteomics Bioinform 12:210\u2013220","journal-title":"Genomics Proteomics Bioinform"},{"issue":"1","key":"17_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O et al (2019) Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10(1):1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6","journal-title":"Nat Commun"},{"key":"17_CR27","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/nn.3829","volume":"17","author":"RR Kitchen","year":"2014","unstructured":"Kitchen RR, Rozowsky JS, Gerstein MB, Nairn AC (2014) Decoding neuroproteomics: integrating the genome, translatome and functional anatomy. Nat Neurosci 17:1491\u20131499","journal-title":"Nat Neurosci"},{"key":"17_CR28","first-page":"11","volume":"75","author":"S Iritani","year":"2013","unstructured":"Iritani S (2013) What happens in the brain of schizophrenia patients? An investigation from the viewpoint of neuropathology. Nagoya J Med Sci 75:11\u201328","journal-title":"Nagoya J Med Sci"},{"key":"17_CR29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jpsychires.2008.11.006","volume":"43","author":"D Martins-de-Souza","year":"2009","unstructured":"Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Guly\u00e1s E, Eberlin MN et al (2009) Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 43:978\u2013986","journal-title":"J Psychiatr Res"},{"key":"17_CR30","doi-asserted-by":"publisher","first-page":"15034","DOI":"10.1038\/npjschz.2015.34","volume":"1","author":"JS Cassoli","year":"2015","unstructured":"Cassoli JS, Guest PC, Malchow B, Schmitt A, Falkai P, Martins-de-Souza D (2015) Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. NPJ Schizophr 1:15034. https:\/\/doi.org\/10.1038\/npjschz.2015.34","journal-title":"NPJ Schizophr"},{"key":"17_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.biopsych.2010.06.031","volume":"69","author":"JA English","year":"2011","unstructured":"English JA, Pennington K, Dunn MJ, Cotter DR (2011) The neuroproteomics of schizophrenia. Biol Psychiatry 69:163\u2013172","journal-title":"Biol Psychiatry"},{"key":"17_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00406-008-0847-2","volume":"259","author":"D Martins-de-Souza","year":"2009","unstructured":"Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E et al (2009) Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 259:151\u2013163","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"17_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jpsychires.2009.07.007","volume":"44","author":"D Martins-de-Souza","year":"2010","unstructured":"Martins-de-Souza D (2010) Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J Psychiatr Res 44:149\u2013156","journal-title":"J Psychiatr Res"},{"key":"17_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00406-015-0621-1","volume":"265","author":"VM Saia-Cereda","year":"2015","unstructured":"Saia-Cereda VM, Cassoli JS, Schmitt A, Falkai P, Nascimento JM, Martins-de-Souza D (2015) Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. Eur Arch Psychiatry Clin Neurosci 265:601\u2013612","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"17_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2016.03.022","volume":"177","author":"VM Saia-Cereda","year":"2016","unstructured":"Saia-Cereda VM, Cassoli JS, Schmitt A, Falkai P, Martins-de-Souza D (2016) Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. Schizophr Res 177:70\u201377","journal-title":"Schizophr Res"},{"key":"17_CR36","doi-asserted-by":"publisher","first-page":"103814","DOI":"10.1016\/j.jprot.2020.103814","volume":"223","author":"G Reis-de-Oliveira","year":"2020","unstructured":"Reis-de-Oliveira G, Zuccoli GS, Fioramonte M, Schimitt A, Falkai P, Almeida V et al (2020) Digging deeper in the proteome of different regions from schizophrenia brains. J Proteome 223:103814. https:\/\/doi.org\/10.1016\/j.jprot.2020.103814. Online ahead of print","journal-title":"J Proteome"},{"key":"17_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.schres.2016.04.050","volume":"177","author":"R Pinacho","year":"2016","unstructured":"Pinacho R, Villalmanzo N, Meana JJ, Ferrer I, Berengueras A, Haro JM et al (2016) Altered CSNK1E, FABP4 and NEFH protein levels in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res 177:88\u201397","journal-title":"Schizophr Res"},{"key":"17_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.schres.2016.03.002","volume":"177","author":"VE Barakauskas","year":"2016","unstructured":"Barakauskas VE, Moradian A, Barr AM, Beasley CL, Rosoklija G, Mann JJ et al (2016) Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia. Schizophr Res 177:44\u201351","journal-title":"Schizophr Res"},{"key":"17_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.schres.2015.02.002","volume":"167","author":"KO Schubert","year":"2015","unstructured":"Schubert KO, F\u00f6cking M, Cotter DR (2015) Proteomic pathway analysis of the hippocampus in schizophrenia and bipolar affective disorder implicates 14-3-3 signaling, aryl hydrocarbon receptor signaling, and glucose metabolism: potential roles in GABAergic interneuron pathology. Schizophr Res 167:64\u201372","journal-title":"Schizophr Res"},{"key":"17_CR40","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1021\/acs.jproteome.7b00422","volume":"16","author":"E Vel\u00e1squez","year":"2017","unstructured":"Vel\u00e1squez E, Nogueira FCS, Vel\u00e1squez I, Schmitt A, Falkai P, Domont GB et al (2017) Synaptosomal proteome of the orbitofrontal cortex from schizophrenia patients using quantitative label-free and iTRAQ-based shotgun proteomics. J Proteome Res 16:4481\u20134494","journal-title":"J Proteome Res"},{"key":"17_CR41","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/mp.2014.63","volume":"20","author":"M F\u00f6cking","year":"2015","unstructured":"F\u00f6cking M, Lopez LM, English JA, Dicker P, Wolff A, Brindley E et al (2015) Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia. Mol Psychiatry 20:424\u2013432","journal-title":"Mol Psychiatry"},{"key":"17_CR42","first-page":"37","volume":"3","author":"VM Saia-Cereda","year":"2017","unstructured":"Saia-Cereda VM, Santana AG, Schmitt A, Falkai P, Martins-de-Souza D (2017) The nuclear proteome of white and gray matter from schizophrenia postmortem brains. Mol Neuropsychiatry 3:37\u201352","journal-title":"Mol Neuropsychiatry"},{"key":"17_CR43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/hmg\/ddh065","volume":"13","author":"JZ Li","year":"2004","unstructured":"Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary PV et al (2004) Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 13:609\u2013616","journal-title":"Hum Mol Genet"},{"key":"17_CR44","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ajmg.b.31062","volume":"153B","author":"B Rollins","year":"2010","unstructured":"Rollins B, Martin MV, Morgan L, Vawter MP (2010) Analysis of whole genome biomarker expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 153B:919\u2013936","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"17_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.schres.2007.09.020","volume":"98","author":"RP Sharma","year":"2008","unstructured":"Sharma RP, Grayson DR, Gavin DP (2008) Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection. Schizophr Res 98:111\u2013117","journal-title":"Schizophr Res"},{"issue":"1","key":"17_CR46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41398-019-0461-2","volume":"9","author":"A Yoshimi","year":"2019","unstructured":"Yoshimi A, Yamada S, Kunimoto S, Aleksic B, Hirakawa A, Ohashi M et al (2019) Proteomic analysis of lymphoblastoid cell lines from schizophrenic patients. Transl Psychiatry 9(1):126. https:\/\/doi.org\/10.1038\/s41398-019-0461-2","journal-title":"Transl Psychiatry"},{"issue":"12","key":"17_CR47","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41398-017-0027-0","volume":"7","author":"JD Cooper","year":"2017","unstructured":"Cooper JD, Ozcan S, Gardner RM, Rustogi N, Wicks S, van Rees GF et al (2017) Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots. Transl Psychiatry 7(12):1290. https:\/\/doi.org\/10.1038\/s41398-017-0027-0","journal-title":"Transl Psychiatry"},{"key":"17_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00406-016-0724-3","volume":"267","author":"C Kn\u00f6chel","year":"2017","unstructured":"Kn\u00f6chel C, Kniep J, Cooper JD, St\u00e4blein M, Wenzler S, Sarlon J et al (2017) Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder. Eur Arch Psychiatry Clin Neurosci 267:199\u2013212","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"17_CR49","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1038\/s41467-019-11797-3","volume":"10","author":"J Tiihonen","year":"2019","unstructured":"Tiihonen J, Koskuvi M, Storvik M, Hy\u00f6tyl\u00e4inen I, Gao Y, Puttonen KA et al (2019) Sex-specific transcriptional and proteomic signatures in schizophrenia. Nat Commun 10(1):3933. https:\/\/doi.org\/10.1038\/s41467-019-11797-3","journal-title":"Nat Commun"},{"key":"17_CR50","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"O-B Tysnes","year":"2017","unstructured":"Tysnes O-B, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm 124:901\u2013905","journal-title":"J Neural Transm"},{"key":"17_CR51","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LML de Lau","year":"2006","unstructured":"de Lau LML, Breteler MMB (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5:525\u2013535","journal-title":"Lancet Neurol"},{"issue":"2","key":"17_CR52","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L (2012) \u03b1-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2(2):a009399. https:\/\/doi.org\/10.1101\/cshperspect.a009399","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"17_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/biology8020038","volume":"8","author":"C Chen","year":"2019","unstructured":"Chen C, Turnbull DM, Reeve AK (2019) Mitochondrial dysfunction in Parkinson\u2019s disease-cause or consequence? Biology 8(2):38. https:\/\/doi.org\/10.3390\/biology8020038","journal-title":"Biology"},{"key":"17_CR54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41591-019-0739-1","volume":"26","author":"AH Laperle","year":"2020","unstructured":"Laperle AH, Sances S, Yucer N, Dardov VJ, Garcia VJ, Ho R et al (2020) iPSC modeling of young-onset Parkinson\u2019s disease reveals a molecular signature of disease and novel therapeutic candidates. Nat Med 26:289\u2013299","journal-title":"Nat Med"},{"key":"17_CR55","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1073\/pnas.1905057117","volume":"117","author":"P Zhang","year":"2020","unstructured":"Zhang P, Park H-J, Zhang J, Junn E, Andrews RJ, Velagapudi SP et al (2020) Translation of the intrinsically disordered protein \u03b1-synuclein is inhibited by a small molecule targeting its structured mRNA. Proc Natl Acad Sci U S A 117:1457\u20131467","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17_CR56","doi-asserted-by":"publisher","first-page":"180036","DOI":"10.1038\/sdata.2018.36","volume":"5","author":"L Ping","year":"2018","unstructured":"Ping L, Duong DM, Yin L, Gearing M, Lah JJ, Levey AI et al (2018) Global quantitative analysis of the human brain proteome in Alzheimer\u2019s and Parkinson's disease. Sci Data 5:180036. https:\/\/doi.org\/10.1038\/sdata.2018.36","journal-title":"Sci Data"},{"key":"17_CR57","doi-asserted-by":"publisher","first-page":"24310","DOI":"10.1073\/pnas.1903268116","volume":"116","author":"YV Taguchi","year":"2019","unstructured":"Taguchi YV, Gorenberg EL, Nagy M, Thrasher D, Fenton WA, Volpicelli-Daley L et al (2019) Hsp110 mitigates \u03b1-synuclein pathology in vivo. Proc Natl Acad Sci U S A 116:24310\u201324316","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17_CR58","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MHR Ludtmann","year":"2018","unstructured":"Ludtmann MHR, Angelova PR, Horrocks MH, Choi ML, Rodrigues M, Baev AY et al (2018) \u03b1-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease. Nat Commun 9:2293. https:\/\/doi.org\/10.1038\/s41467-018-04422-2","journal-title":"Nat Commun"},{"key":"17_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0736-0","volume":"7","author":"V Donega","year":"2019","unstructured":"Donega V, Burm SM, van Strien ME, van Bodegraven EJ, Paliukhovich I, Geut H et al (2019) Transcriptome and proteome profiling of neural stem cells from the human subventricular zone in Parkinson\u2019s disease. Acta Neuropathol Commun 7:84. https:\/\/doi.org\/10.1186\/s40478-019-0736-0","journal-title":"Acta Neuropathol Commun"},{"key":"17_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002931","volume":"16","author":"M Posavi","year":"2019","unstructured":"Posavi M, Diaz-Ortiz M, Liu B, Swanson CR, Skrinak RT, Hernandez-Con P et al (2019) Characterization of Parkinson\u2019s disease using blood-based biomarkers: A multicohort proteomic analysis. PLoS Med 16:e1002931. https:\/\/doi.org\/10.1371\/journal.pmed.1002931","journal-title":"PLoS Med"},{"key":"17_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2019.03.001","volume":"63","author":"M Boerger","year":"2019","unstructured":"Boerger M, Funke S, Leha A, Roser A-E, Wuestemann A-K, Maass F et al (2019) Proteomic analysis of tear fluid reveals disease-specific patterns in patients with Parkinson\u2019s disease\u2014a pilot study. Parkinsonism Relat Disord 63:3\u20139","journal-title":"Parkinsonism Relat Disord"},{"key":"17_CR62","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fnmol.2017.00276","volume":"10","author":"F Ciregia","year":"2017","unstructured":"Ciregia F, Urbani A, Palmisano G (2017) Extracellular vesicles in brain tumors and neurodegenerative diseases. Front Mol Neurosci 10:276. https:\/\/doi.org\/10.3389\/fnmol.2017.00276","journal-title":"Front Mol Neurosci"},{"key":"17_CR63","doi-asserted-by":"publisher","first-page":"e17478","DOI":"10.1097\/MD.0000000000017478","volume":"98","author":"R Jiang","year":"2019","unstructured":"Jiang R, Rong C, Ke R, Meng S, Yan X, Ke H et al (2019) Differential proteomic analysis of serum exosomes reveals alterations in progression of Parkinson disease. Medicine 98:e17478. https:\/\/doi.org\/10.1097\/MD.0000000000017478","journal-title":"Medicine"},{"issue":"1","key":"17_CR64","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbrc.2011.07.027","volume":"412","author":"H Welander","year":"2011","unstructured":"Welander H, Bontha SV, N\u00e4sstr\u00f6m T, Karlsson M, Nikolajeff F, Danzer K et al (2011) Gelsolin co-occurs with Lewy bodies in vivo and accelerates \u03b1-synuclein aggregation in vitro. Biochem Biophys Res Commun 412(1):32\u201338","journal-title":"Biochem Biophys Res Commun"},{"key":"17_CR65","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s12031-019-01411-y","volume":"69","author":"S Zhu","year":"2019","unstructured":"Zhu S, Wuolikainen A, Wu J, \u00d6hman A, Wingsle G, Moritz T et al (2019) Targeted multiple reaction monitoring analysis of CSF identifies UCHL1 and GPNMB as candidate biomarkers for ALS. J Mol Neurosci 69:643\u2013657","journal-title":"J Mol Neurosci"},{"key":"17_CR66","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1002\/pmic.201600057","volume":"16","author":"CM Hales","year":"2016","unstructured":"Hales CM, Dammer EB, Deng Q, Duong DM, Gearing M, Troncoso JC et al (2016) Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer\u2019s disease progression. Proteomics 16:3042\u20133053","journal-title":"Proteomics"},{"key":"17_CR67","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13024-018-0282-4","volume":"13","author":"ECB Johnson","year":"2018","unstructured":"Johnson ECB, Dammer EB, Duong DM, Yin L, Thambisetty M, Troncoso JC et al (2018) Deep proteomic network analysis of Alzheimer\u2019s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol Neurodegener 13:52. https:\/\/doi.org\/10.1186\/s13024-018-0282-4","journal-title":"Mol Neurodegener"},{"key":"17_CR68","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jalz.2017.01.021","volume":"13","author":"F Baldacci","year":"2017","unstructured":"Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I et al (2017) Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer\u2019s disease. Alzheimers Dement 13:993\u20131003","journal-title":"Alzheimers Dement"},{"key":"17_CR69","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15:673\u2013684","journal-title":"Lancet Neurol"},{"key":"17_CR70","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14789450.2017.1304217","volume":"14","author":"F Baldacci","year":"2017","unstructured":"Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H (2017) Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer\u2019s disease and other neurodegenerative diseases. Expert Rev Proteomics 14:285\u2013299","journal-title":"Expert Rev Proteomics"},{"key":"17_CR71","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, Skillb\u00e4ck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM et al (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol 73:60\u201367","journal-title":"JAMA Neurol"},{"key":"17_CR72","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.neuint.2017.05.010","volume":"108","author":"S Lista","year":"2017","unstructured":"Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I et al (2017) Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer\u2019s disease. Neurochem Int 108:355\u2013360","journal-title":"Neurochem Int"},{"key":"17_CR73","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14737175.2016.1204234","volume":"17","author":"S Lista","year":"2017","unstructured":"Lista S, Hampel H (2017) Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer\u2019s disease. Expert Rev Neurother 17:47\u201357","journal-title":"Expert Rev Neurother"},{"key":"17_CR74","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer\u2019s disease. Lancet 368:387\u2013403","journal-title":"Lancet"},{"key":"17_CR75","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature 375:754\u2013760","journal-title":"Nature"},{"key":"17_CR76","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"E Levy-Lahad","year":"1995","unstructured":"Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH et al (1995) Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science 269:973\u2013977","journal-title":"Science"},{"key":"17_CR77","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0140-6736(93)91705-Q","volume":"342","author":"J Poirier","year":"1993","unstructured":"Poirier J, Bertrand P, Poirier J, Kogan S, Gauthier S, Poirier J et al (1993) Apolipoprotein E polymorphism and Alzheimer\u2019s disease. Lancet 342:697\u2013699","journal-title":"Lancet"},{"key":"17_CR78","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","volume":"88","author":"SM de la Monte","year":"2014","unstructured":"de la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer\u2019s disease. Biochem Pharmacol 88:548\u2013559","journal-title":"Biochem Pharmacol"},{"key":"17_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-981-13-3540-2_4","volume":"1128","author":"SM de la Monte","year":"2019","unstructured":"de la Monte SM (2019) The full spectrum of Alzheimer\u2019s disease is rooted in metabolic derangements that drive type 3 diabetes. Adv Exp Med Biol 1128:45\u201383","journal-title":"Adv Exp Med Biol"},{"key":"17_CR80","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med 284:643\u2013663","journal-title":"J Intern Med"},{"key":"17_CR81","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.18632\/aging.101638","volume":"10","author":"D Ferreira","year":"2018","unstructured":"Ferreira D, Wahlund L-O, Westman E (2018) The heterogeneity within Alzheimer\u2019s disease. Aging 10:3058\u20133060","journal-title":"Aging"},{"key":"17_CR82","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.2174\/138161211797416039","volume":"17","author":"E Portelius","year":"2011","unstructured":"Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H (2011) Novel a\u03b2 isoforms in Alzheimer\u2019s disease\u2014their role in diagnosis and treatment. Curr Pharm Des 17:2594\u20132602","journal-title":"Curr Pharm Des"},{"key":"17_CR83","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3233\/JAD-2012-121471","volume":"33","author":"J Pannee","year":"2013","unstructured":"Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I et al (2013) A selected reaction monitoring (SRM)-based method for absolute quantification of A\u03b238, A\u03b240, and A\u03b242 in cerebrospinal fluid of Alzheimer\u2019s disease patients and healthy controls. J Alzheimers Dis 33:1021\u20131032","journal-title":"J Alzheimers Dis"},{"key":"17_CR84","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1074\/mcp.M113.028639","volume":"13","author":"SH Han","year":"2014","unstructured":"Han SH, Kim JS, Lee Y, Choi H, Kim JW, Na DL et al (2014) Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer\u2019s disease patients. Mol Cell Proteomics 13:407\u2013419","journal-title":"Mol Cell Proteomics"},{"key":"17_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S et al (2019) Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019s disease. Acta Neuropathol Commun 7:169. https:\/\/doi.org\/10.1186\/s40478-019-0795-2","journal-title":"Acta Neuropathol Commun"},{"key":"17_CR86","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cels.2016.11.006","volume":"4","author":"NT Seyfried","year":"2017","unstructured":"Seyfried NT, Dammer EB, Swarup V, Nandakumar D, Duong DM, Yin L et al (2017) A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer\u2019s disease. Cell Syst 4:60\u201372.e4","journal-title":"Cell Syst"},{"key":"17_CR87","doi-asserted-by":"publisher","first-page":"e63644","DOI":"10.1371\/journal.pone.0063644","volume":"8","author":"E Trushina","year":"2013","unstructured":"Trushina E, Dutta T, Persson X-MT, Mielke MM, Petersen RC (2013) Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer\u2019s disease using metabolomics. PLoS One 8:e63644. https:\/\/doi.org\/10.1371\/journal.pone.0063644","journal-title":"PLoS One"},{"key":"17_CR88","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41591-020-0815-6","volume":"26","author":"ECB Johnson","year":"2020","unstructured":"Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L et al (2020) Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med 26:769\u2013780","journal-title":"Nat Med"},{"key":"17_CR89","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/08039480902767286","volume":"63","author":"BR Rund","year":"2009","unstructured":"Rund BR (2009) Is schizophrenia a neurodegenerative disorder? Nord J Psychiatry 63:196\u2013201","journal-title":"Nord J Psychiatry"},{"key":"17_CR90","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1159\/000369214","volume":"15","author":"J Rao","year":"2015","unstructured":"Rao J, Chiappelli J, Kochunov P, Regenold WT, Rapoport SI, Hong LE (2015) Is schizophrenia a neurodegenerative disease? Evidence from age-related decline of brain-derived neurotrophic factor in the brains of schizophrenia patients and matched nonpsychiatric controls. Neurodegener Dis 15:3844","journal-title":"Neurodegener Dis"},{"key":"17_CR91","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0006-3223(99)00147-X","volume":"46","author":"JA Lieberman","year":"1999","unstructured":"Lieberman JA (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46:729\u2013739","journal-title":"Biol Psychiatry"},{"key":"17_CR92","doi-asserted-by":"publisher","unstructured":"Novellino F, Sacc\u00e0 V, Donato A, Zaffino P, Spadea MF, Vismara M et al (2020) Innate immunity: a common denominator between neurodegenerative and neuropsychiatric diseases. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21031115","DOI":"10.3390\/ijms21031115"},{"key":"17_CR93","doi-asserted-by":"publisher","first-page":"e1800042","DOI":"10.1002\/bies.201800042","volume":"41","author":"A Arora","year":"2019","unstructured":"Arora A, Somasundaram K (2019) Targeted proteomics comes to the benchside and the bedside: is it ready for us? BioEssays 41:e1800042. https:\/\/doi.org\/10.1002\/bies.201800042","journal-title":"BioEssays"},{"key":"17_CR94","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jpba.2018.08.024","volume":"161","author":"V H\u00e1da","year":"2018","unstructured":"H\u00e1da V, Bagdi A, Bihari Z, Tim\u00e1ri SB, Fizil \u00c1, Sz\u00e1ntay C Jr (2018) Recent advancements, challenges, and practical considerations in the mass spectrometry-based analytics of protein biotherapeutics: a viewpoint from the biosimilar industry. J Pharm Biomed Anal 161:214\u2013238","journal-title":"J Pharm Biomed Anal"}],"container-title":["Advances in Experimental Medicine and Biology","Reviews on New Drug Targets in Age-Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-55035-6_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T03:12:30Z","timestamp":1698030750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-55035-6_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030550349","9783030550356"],"references-count":94,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-55035-6_17","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"17 March 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}